EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema

Yoko Takatsuna iD, Ryoichi Ishibashi, Tomoaki Tatsumi, Masaya Koshizaka, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote

Case Reports in Ophthalmological Medicine · 12.11.2020 · 2020 · 1-6

DOI: 10.1155/2020/8867079 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Ophthalmological Medicine, erschienen am 12.11.2020. Verfasst von Yoko Takatsuna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Chiba, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Diabetic macular edema (DME) is a vision-threatening condition that develops in diabetic patients. The first-line therapy for DME is intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents; however, the high frequency of repeat injections, invasiveness of the procedure, and high cost are drawbacks for this treatment. The purpose of this report is to present our findings in 3 patients with chronic DME whose edema was resolved soon after oral doses of sodium-glucose cotransporter-2 (SGLT2) inhibitors were used. Case Presentation. Case 1 was a 66-year-old woman diagnosed with moderate nonproliferative diabetic retinopathy (DR) with DME that had developed a decade earlier. The DME persisted for 4 years in the left eye. The addition of oral empagliflozin, a SGLT2 inhibitor, led to a marked improvement of the DME after one month, and this improvement continued over two years. Case 2 was a 68-year-old woman who was diagnosed with preproliferative DR with bilateral DME. The addition of oral dapagliflozin led to the improvement of the DME after two months, and this improvement continued over one year. Case 3 was a 61-year-old woman who was diagnosed with moderate nonproliferative DR with DME. Oral luseogliflozin was given which led to better glycemic control, and her left central retinal thickness (CRT) was markedly reduced after only two weeks. This reduction was maintained in her left eye for six months without any additional ophthalmic procedures.

Conclusions

Although this study involved only three cases, our findings indicate that SGLT2 inhibitors might have possible efficacy for chronic DME.

Autor:innen und Institutionen

  • Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Chiba, Japan.
  • Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan.
  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan.
  • Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Division of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Chiba, Japan.

ORCID-Profile: Yoko Takatsuna

Zitieren

APA

Takatsuna, Y., Ishibashi, R., Tatsumi, T., Koshizaka, M., Baba, T., Yamamoto, S., & Yokote, K. (2020). Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema. Case Reports in Ophthalmological Medicine, 2020, 1-6. https://doi.org/10.1155/2020/8867079

Vancouver

Takatsuna Y, Ishibashi R, Tatsumi T, Koshizaka M, Baba T, Yamamoto S, et al. Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema. Case Reports in Ophthalmological Medicine. 2020;2020:1-6. doi:10.1155/2020/8867079

BibTeX
@article{Takatsuna2020,
  author = {Takatsuna, Yoko and Ishibashi, Ryoichi and Tatsumi, Tomoaki and Koshizaka, Masaya and Baba, Takayuki and Yamamoto, Shuichi and Yokote, Koutaro},
  title = {Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema},
  journal = {Case Reports in Ophthalmological Medicine},
  year = {2020},
  volume = {2020},
  pages = {1--6},
  doi = {10.1155/2020/8867079}
}
Kostenlos starten →